Safety and Effectiveness Evaluation of Two Kinds of Peritoneal Dialysate

Inclusion Criteria: * Age ≥18, male or female * Patients with end stage renal diseases * Dialysis mode: CAPD * Dialysis duration:≥30 days and ≤6 months * Be capable of implementing home dialysis * Diabetic nephropathy, 3ml/min≤ residual renal GFR ≤15ml/min; other renal diseases, 3ml/min≤ residual renal GFR ≤10ml/min * Sign the written informed consent Exclusion Criteria: * Acute renal failure * Planing to receive kidney transplantation in 2 years * Hemodialysis * Exit site infection or tunnel infection * Presenting 2/3 of the following: a. abdominal pain, turbid ascites, with or without fever; b. drainage fluid WBC\>100×106/L, neutrophil ratio\>50%; c.culture positive/ Gram stain positive in drainage fluid; * Anti-HIV positive * Allergic to components of dialysate * Active, residual malignant tumor, or systemic infection, liver cirrhosis, severe congestive heart failure, anemia（Hb\<80g/L）,malnutrition（Serum Alb\<28g/L）,refractory hypertension * Identified peritoneal high transportation by peritoneal equilibration test (PET) * Extreme body shape (height\> 185cm or height \<145cm), obesity (BMI ≥ 33kg/m2) * Poor compliance * Pregnant or lactating, women of childbearing age do not agree to use effective contraceptive measures during the trial * Has a history of alcoholism and drug abuse (defined as illegal drugs) * Any circumstances when patients are believed unsuitable for this trial